GSA Capital Partners LLP Buys Shares of 53,402 Dynavax Technologies Corporation $DVAX

GSA Capital Partners LLP acquired a new stake in Dynavax Technologies Corporation (NASDAQ:DVAX) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 53,402 shares of the biopharmaceutical company’s stock, valued at approximately $530,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Marshall Wace LLP raised its holdings in shares of Dynavax Technologies by 107.2% during the second quarter. Marshall Wace LLP now owns 1,814,934 shares of the biopharmaceutical company’s stock valued at $18,004,000 after buying an additional 939,076 shares during the last quarter. Bank of America Corp DE raised its stake in Dynavax Technologies by 32.0% during the 2nd quarter. Bank of America Corp DE now owns 1,159,981 shares of the biopharmaceutical company’s stock valued at $11,507,000 after acquiring an additional 281,104 shares in the last quarter. Nordea Investment Management AB raised its stake in Dynavax Technologies by 3.3% during the 3rd quarter. Nordea Investment Management AB now owns 808,157 shares of the biopharmaceutical company’s stock valued at $7,908,000 after acquiring an additional 25,909 shares in the last quarter. Peregrine Capital Management LLC boosted its position in Dynavax Technologies by 1.8% during the 2nd quarter. Peregrine Capital Management LLC now owns 688,896 shares of the biopharmaceutical company’s stock worth $6,834,000 after acquiring an additional 11,878 shares during the period. Finally, Hudson Bay Capital Management LP grew its stake in shares of Dynavax Technologies by 46.4% in the second quarter. Hudson Bay Capital Management LP now owns 541,600 shares of the biopharmaceutical company’s stock worth $5,373,000 after purchasing an additional 171,700 shares in the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on DVAX shares. Wall Street Zen raised shares of Dynavax Technologies to a “strong-buy” rating in a report on Saturday, February 14th. William Blair downgraded shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $21.00.

Insider Activity at Dynavax Technologies

In related news, COO David F. Novack sold 114,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the completion of the sale, the chief operating officer directly owned 63,344 shares in the company, valued at approximately $990,700.16. This trade represents a 64.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.98% of the company’s stock.

Dynavax Technologies Price Performance

Shares of Dynavax Technologies stock opened at $15.50 on Tuesday. Dynavax Technologies Corporation has a 1 year low of $9.20 and a 1 year high of $15.73. The company has a market cap of $1.82 billion, a P/E ratio of -41.89 and a beta of 0.97. The company has a current ratio of 7.62, a quick ratio of 6.94 and a debt-to-equity ratio of 0.41. The stock has a 50-day moving average price of $14.95 and a 200 day moving average price of $12.00.

Dynavax Technologies Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.